ritonavir%D8%B1%D9%8A%D8%AA%D9%88%D9%86%D8%A7%D9%81%D9%8A%D8%B1ritonavirritonavir%D8%B1%DB%8C%D8%AA%D9%88%D9%86%D8%A7%D9%88%DB%8C%D8%B1ritonavirritonavirritonavir%EB%A6%AC%ED%86%A0%EB%82%98%EB%B9%84%EB%A5%B4ritonavir%E0%AC%B0%E0%AC%BF%E0%AC%9F%E0%AD%8B%E0%AC%A8%E0%AC%BE%E0%AC%AD%E0%AC%BF%E0%AC%B0rytonawirritonavirritonavir%E0%B8%A3%E0%B8%B4%E0%B9%82%E0%B8%95%E0%B8%99%E0%B8%B2%E0%B9%80%E0%B8%A7%E0%B8%B5%E0%B8%A2%E0%B8%A3%E0%B9%8C%D0%A0%D0%B8%D1%82%D0%BE%D0%BD%D0%B0%D0%B2%D1%96%D1%80ritonavirQ3836750%E5%88%A9%E6%89%98%E9%82%A3%E9%9F%8B
about
P2176
BLADE: Comparison of Once Daily Lopinavir/Ritonavir to Lopinavir/Ritonavir BID Dosing in HIV-Infected SubjectsA 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients InfectedA randomized, controlled open-label trial to evaluate the efficacy and safety of lopinavir-ritonavir in hospitalized patients with novel coronavirus pneumonia (COVID-19)
P4844
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trialMethadone-induced Torsade de pointes after stopping lopinavir-ritonavir.Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.Lopinavir/ritonavir: a review of its use in the management of HIV infection.Lopinavir/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: the KALESOLO trial.Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study.Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers.Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV.Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy.Re: Acknowledgement of human bioequivalency of matrix's lopinavir-ritonavir formulation to Kaletra, comment to article on Bioavailability of generic ritonavir and lopinavir/ritonavir tablet products in a dog model, by Garren et al.Once- versus twice-daily lopinavir/ritonavir tablets in virologically suppressed, HIV-infected, treatment-experienced children: comparative pharmacokinetics and virological outcome after switching to once-daily lopinavir/ritonavir.Predictors of loss of virologic response in subjects who simplified to lopinavir/ritonavir monotherapy from lopinavir/ritonavir plus zidovudine/lamivudine.First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir.Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis.Saquinavir plus lopinavir/ritonavir versus amprenavir plus lopinavir/ritonavir for treating highly resistant patients in Brazil.Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers.Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE):Lopinavir/ritonavir + tenofovir Dual Therapy versus Lopinavir/ritonavir-Based Triple Therapy in HIV-Infected Antiretroviral Naïve Subjects: The Kalead StudyA randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR studyFaculty of 1000 evaluation for A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapyPursuing use of optimal formulations for paediatric HIV epidemic control - a look at the use of LPV/r oral pellets and oral granulesLopinavir–ritonavir super-boosting in young HIV-infected children on rifampicin-based tuberculosis therapy compared with lopinavir–ritonavir without rifampicin: a pharmacokinetic modelling and clinical studyA Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort studyA sporadic COVID-19 pneumonia treated with extracorporeal membrane oxygenation in Tokyo, Japan: A case reportTreatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial
P921
Q28256092-be6db06f-4654-5eb6-988c-b06d551ea8b7Q34578756-b3c3fc4f-44a5-b6dd-5ef3-ec791f6d55a0Q34647153-4c8e78d0-4c6b-72b0-7443-b413b262363bQ34652472-c36fc8e1-4a1f-c65d-c9d7-1cb39359add4Q38499842-42dda455-4128-0a9a-c5b0-f6efdc78fccdQ39394695-9cc0e469-4861-592e-d3b5-690736eefefbQ39394704-635db92c-4189-f42a-0fab-05a6eb63f609Q39972769-c32ae0bc-4ca1-5061-3791-503fdc2b95c2Q42640549-40c231ff-48c9-f917-5f9c-0bc0f60eca14Q43102710-9548b63c-4ece-4d8a-1ed9-eca315ce9770Q43278133-8dacee17-4390-3de8-eea0-da6138201604Q43981478-d87526c1-4112-c9c5-189e-9f0a505867f6Q44576691-ee2fde84-4b23-09f1-e932-d02c6203be9cQ46021020-78d9d591-4c8c-2590-70f1-9ea5a4580f6dQ46059384-5367c944-4555-b40b-0ae6-05b1052100a6Q46708529-01b6514d-4f7e-a68a-37de-f757565a9224Q46807881-32ad7a1d-4790-3324-e90e-1b9a9bc78c57Q48705073-804f58f7-41a6-21ee-cf64-76991e8e022cQ56449002-191cb4ca-4494-04c6-2687-71ca3fce77dcQ58290908-ba324416-4b3b-6bbe-3fda-c4713c3a58deQ58815112-dd8149a8-456d-7825-429e-4ea61360735dQ58866110-de900bb9-44b8-93ba-c092-fb13f49019fdQ64113877-37122E14-BC8D-40AB-8380-EAE900C14CB4Q64385639-8b22381a-4888-5a66-60d5-3fee4b0ae71eQ88370045-bcccf094-4fe6-0594-7c36-7c5a44311aa0Q90327975-92630386-2132-42FA-85D1-67B16D881E86Q92128147-22123D7D-F3AF-4B76-B970-E12AAB3755CFQ92333096-E4D70327-E543-4B89-B55E-6DC923BAE34A
P921
description
HIV-Kombinationspräparat
@de
chemische stof
@nl
combination drug for HIV
@en
քիմիական միացություն
@hy
name
Kaletra
@pl
Kaletra
@pt
Lopinavir/Ritonavir
@de
Lopinavir/ritonavir
@af
Lopinavir/ritonavir
@es
Lopinavir/ritonavir
@nl
Lopinavir/ritonavir
@ro
lopinavir/ritonavir
@ca
lopinavir/ritonavir
@da
lopinavir/ritonavir
@en
type
label
Kaletra
@pl
Kaletra
@pt
Lopinavir/Ritonavir
@de
Lopinavir/ritonavir
@af
Lopinavir/ritonavir
@es
Lopinavir/ritonavir
@nl
Lopinavir/ritonavir
@ro
lopinavir/ritonavir
@ca
lopinavir/ritonavir
@da
lopinavir/ritonavir
@en
altLabel
Lopinavir–Ritonavir
@en
lopinavir / ritonavir
@en
lopinavir-ritonavir
@en
lopinavir/ritonavir
@en
كاليترا
@ar
アルビア(薬剤)
@ja
合剤
@ja
prefLabel
Kaletra
@pl
Kaletra
@pt
Lopinavir/Ritonavir
@de
Lopinavir/ritonavir
@af
Lopinavir/ritonavir
@es
Lopinavir/ritonavir
@nl
Lopinavir/ritonavir
@ro
lopinavir/ritonavir
@ca
lopinavir/ritonavir
@da
lopinavir/ritonavir
@en
P31
P6366
P661
P662
P665
P2017
CC1=C(C(=CC=C1)C)OCC(=O)N[C@@H ...... 3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O
P2065
P2115
N0000022203
P231
369372-47-4
P233
CC1=C(C(=CC=C1)C)OCC(=O)NC(CC2 ...... 3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O
P235
OFFWOVJBSQMVPI-RMLGOCCBSA-N
P267
P3117
DTXSID30190428